Patient population and baseline characteristics
NSCLC, PD, anaplastic lymphoma
METASTASIS, DISEASE, LUNG CANCER, ADVERSE EVENT, NSCLC
The first patient was enrolled on December 11, 2017 (study initiation date), and the results reported here are based on a data cutoff date of November 05, 2019, at which point all patients had either completed 12 months of treatment, or had withdrawn from the study.In total, 651 patients were randomized (325 in the BAT1706 arm and 326 in the EU‐bevacizumab arm) and comprised the ITT population (Figure Patient disposition. ITT, intention‐to‐treat; ORR, overall response rate; PD, progressive disease; PK, pharmacokinetic; PP, per protocol; TEAE, treatment‐emergent adverse event.Demographic and baseline characteristics of patients were similar for both treatment arms (Table Demographic and baseline—ITT population.
Abbreviations: ALK, anaplastic lymphoma kinase; ECOG, eastern cooperative oncology group; EGFR, epidermal growth factor receptor; ITT, intention‐to‐treat; min, minimum; max, maximum; NSCLC, non‐small cell lung cancer; ROS, receptor tyrosine kinase; SD, standard deviation.Time since initial NSCLC diagnosis (months) = (date of informed consent form – date of initial NSCLC diagnosis +1)/30.4375.Time since first metastasis (months) = (date of informed consent form – date of first metastasis +1)/30.4375.Time since first metastasis (months) = (date of randomization – date of first metastasis +1)/30.4375.